GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy

References

• World Health Organization. Obesity and overweight. Geneva: WHO; 2017.
   Google Scholar
• World Obesity Federation. World obesity atlas. 2022
   Google Scholar
• World Health Organization. European regional obesity report 2022. Copenhagen: WHO; 2022
   Google Scholar
• Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study. Circulation. 1983;67:968–977.
   PubMed Web of Science ®Google Scholar
• Leitner DR, Frühbeck G, Yumuk V, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies - EASO can lead the way. Obes Facts. 2017;10:483–492.
   PubMed Web of Science ®Google Scholar
• Pegueroles J, Jiménez A, Vilaplana E, et al. Obesity and Alzheimer’s disease, does the obesity paradox really exist? A magnetic resonance imaging study. Oncotarget. 2018;9:34691–34698.
   PubMedGoogle Scholar
• Naderali EK, Ratcliffe SH, Dale MC. Obesity and Alzheimer’s disease: a link between body weight and cognitive function in old age. Am J Alzheimers Dis Other Demen. 2010;24:445–449
   Google Scholar
• Kyle TK, Dhurandhar EJ, Allison DB. Regarding obesity as a disease: evolving policies and their implications. Endocrinol Metab Clin North Am. 2016;45:511–520
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute (NIH publication 98-4083). The evidence report, clinical guidelines on the identification, evaluation, treatment of overweight and obesity in adults. 1998. Available from: http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf. [cited 2022 Nov 8]
   Google Scholar
• Baillot A, Romain AJ, Boisvert-Vigneault K, et al. Effects of lifestyle interventions that include a physical activity component in class II and III obese individuals: a systematic review and meta-analysis. PLoS One. 2015;10:e0119017.
   PubMed Web of Science ®Google Scholar
• Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology. 2007;132:2253–2271.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Laverty AA, Aasheim E, et al. Eligibility for bariatric surgery among adults in England: analysis of a national cross-sectional survey. JRSM Open. 2014;5:2042533313512479.
   Google Scholar
• Czernichow S, Batty GD. Withdrawal of sibutramine for weight loss: where does this leave clinicians? Obes. Facts. 2010;3(3):155–156.
   PubMedGoogle Scholar
• Smith SR, Weissman NJ, Anderson CM, et al. Behavioural modification and lorcaserin for overweight and obesity management (BLOOM) study group. Multicentre, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–256.
   PubMed Web of Science ®Google Scholar
• Blasio A, Iemolo A, Sabino V, et al. Rimonabant precipitates anxiety in rats withdrawn from palatable food: role of the central amygdala. Neuropsychopharmacology. 2013;38:2498–2507.
   PubMedGoogle Scholar
• Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21:12–23.
   PubMed Web of Science ®Google Scholar
• Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Eng J Med. 2020;382:2117–2128.
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989.
   PubMed Web of Science ®Google Scholar
• Buhls T, Thimq L, Kofodll H, et al. Naturally occurring products of proglucagon 11 1-160 in the porcine and human small intestine. J Biol Chem. 1988;263:8621–8624.
   PubMedGoogle Scholar
• Reimann F, Gribble FM. Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes. 2002;51:2757–2763.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157.
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol. 1996;318:429–435.
   PubMed Web of Science ®Google Scholar
• Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007;113:546–593.
   PubMed Web of Science ®Google Scholar
• Moffett RC, Patterson S, Irwin N, et al. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes. Diabetes Metab Res Rev. 2015;31:248–255
   PubMedGoogle Scholar
• Vasu S, Moffett RC, Thorens B, et al. Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress. PLoS One. 2014;9:e101005.
   PubMedGoogle Scholar
• De Marinis YZ, Salehi A, Ward CE, et al. GLP-1 inhibits and Adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. Cell Metab. 2010;11:543–553.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80(3):952–957.
   PubMed Web of Science ®Google Scholar
• Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from Guinea pig pancreas. J Biol Chem. 1992;267:7402–7405.
   PubMed Web of Science ®Google Scholar
• Edwards CMB, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol – Endocrinol Metab. 2001;281:155–161
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Heal Pharm. 2005;62:173–181.
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30:1608–1610.
   PubMed Web of Science ®Google Scholar
• Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:834–844.
   PubMed Web of Science ®Google Scholar
• Jendle J, Grunberger G, Blevins T, et al. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016;32:776–790
   PubMed Web of Science ®Google Scholar
• Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:528–539.
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–830.
   PubMed Web of Science ®Google Scholar
• Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014;15(3):181–187.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. J Am Med Assoc. 2015;314:687–699.
   PubMed Web of Science ®Google Scholar
• Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab. 2009;11(3)26–34.
   PubMedGoogle Scholar
• Weiss T, Carr RD, Pal S, et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer Adherence. 2020;27(14):2337–2345.
   Google Scholar
• Sikirica MV, Martin AA, Wood R, et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;29(10):403–412.
   Google Scholar
• Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39:231–241.
   PubMed Web of Science ®Google Scholar
• Frías JP, Auerbach P, Bajaj, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes. Endocrinol 2021;9(9):563–574.
   Google Scholar
• Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42:2262–2271.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT05132088. Available from: https://clinicaltrials.gov/ct2/show/NCT05132088?term=semaglutide&cond=Obesity&draw=2&rank=7. [cited 2022 Nov 15].
   Google Scholar
• Overgaard RV, Navarria A, Ingwersen SH, et al. Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials. Clin Pharmacokinet. 2021;60(10):1335–1348.
   PubMedGoogle Scholar
• Buchan AMJ, Polak JM, Capella C, et al. Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry. 1978;56:37–44.
   PubMedGoogle Scholar
• Pederson RA, Schubert HE, Brown JC. Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog. Diabetes 1975;24:1050–1056.
   PubMed Web of Science ®Google Scholar
• Green BD, Gault VA, Flatt PR, et al. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch Biochem Biophys. 2004;428(2):136–143.
   PubMedGoogle Scholar
• Mommsen TP, Mojsov S. Glucagon-like peptide-1 activates the adenylyl cyclase system in rockfish enterocytes and brain membranes. Comp Biochem Physiol B Biochem Mol Biol. 1998;121(1)49–56.
   PubMedGoogle Scholar
• Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐ 1(7–36)amide,peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829–835.
   PubMedGoogle Scholar
• Deacon CF, Plamboeck A, Rosenkilde MM, et al. GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. Am J Physiol Endocrinol Metab. 2006;291(3):E468–75.
   PubMedGoogle Scholar
• Gault VA, Parker JC, Harriott P, et al. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol. 2002;175(2):525–533.
   PubMed Web of Science ®Google Scholar
• Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010;1:8–23.
   PubMed Web of Science ®Google Scholar
• Samms RJ, Coghlan MP, Sloop KW. How may gip enhance the therapeutic efficacy of GLP-1? Trends Endocrinol. Metab. 2020;31(6):410–421.
   Google Scholar
• Gault VA, Flatt PR, O’Harte FP. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun. 2003;308(2):207–213.
   PubMed Web of Science ®Google Scholar
• Hinke SA, Gelling RW, Pederson RA, et al. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes. 2002;51(3):652–661.
   PubMedGoogle Scholar
• Gault VA, O’Harte FP, Harriott P, et al. Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo. Metabolism. 2003;52(6):679–687.
   PubMedGoogle Scholar
• Gault VA, Flatt PR, Harriott P, et al. Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide. J Endocrinol. 2003;176(1):133–141.
   PubMedGoogle Scholar
• Irwin N, Green BD, Gault VA, et al. Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. J Med Chem. 2005;48(4):12440–12450.
   Google Scholar
• Irwin N, Green BD, Mooney MH, et al. A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. J Pharmacol Exp Ther. 2005;314(3):1187–1194.
   PubMed Web of Science ®Google Scholar
• Irwin N, O’Harte FP, Gault VA, et al. GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J Med Chem. 2006;49(3):1047–1054.
   PubMedGoogle Scholar
• Irwin N, Gault VA, Green BD, et al. Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): n-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). Biol Chem. 2005;386(7):679–687.
   PubMedGoogle Scholar
• Gault VA, Fpm O, Harriott P, et al. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia. 2003;46(2):222–230.
   PubMed Web of Science ®Google Scholar
• Parker JC, Irwin N, Lavery KS, et al. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice. Biol Chem. 2007;388(2):221–226.
   PubMedGoogle Scholar
• Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91(1):301–307.
   PubMed Web of Science ®Google Scholar
• Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14.
   PubMed Web of Science ®Google Scholar
• Irwin N, Gault V, Flatt PR. Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer’s disease? Expert Opin. Investig Drugs. 2010;19(9):1039–1048.
   Google Scholar
• Inagaki N, Takeuchi M, Oura T, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):623–633.
   PubMed Web of Science ®Google Scholar
• Whysham CH, Tofe S, Sapin H, et al. Effect of once-weekly TZP on glycemic control by baseline age in patient subpopulations from the SURPASS trials. Diabetes. 2022;71(1):743.
   Google Scholar
• Rosenstock J, Del Prato S, Franco DR, et al. Characterization of tirzepatide-treated patients achieving HbA1c < 5.7 % in the SURPASS 1–4 trials. Diabetes. 2022;71(1):90.
   Google Scholar
• Syed YY. Tirzepatide: first Approval. Drugs. 2022;82(11):1213–1220.
   PubMed Web of Science ®Google Scholar
• Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22:938–946.
   PubMed Web of Science ®Google Scholar
• Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503–515.
   PubMed Web of Science ®Google Scholar
• Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. J. C. I. Insight. 2020;5:e140532.
   Google Scholar
• Perry RA, Craig SL, Ng MT, et al. Characterisation of glucose-dependent insulinotropic polypeptide receptor antagonists in rodent pancreatic beta cells and mice. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419875453
   Google Scholar
• Tanday N, English A, Lafferty RA, et al. Benefits of sustained upregulated unimolecular GLP-1 and CCK receptor signalling in obesity-diabetes. Front Endocrinol. 2021;14:674704.
   Google Scholar
• Tanday N, Flatt PR, Irwin N. Amplifying the antidiabetic actions of glucagon-like peptide-1: potential benefits of new adjunct therapies. Diabet Med. 2021;38(12):e14699.
   PubMedGoogle Scholar
• Borner T, Geisler CE, Fortin SM, et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes. 2021;70(11):2545–2553.
   PubMedGoogle Scholar
• Gallwitz B, Witt M, Morys-Wortmann C, et al. GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1. Regul Pept. 1996;63(1):17–22.
   PubMedGoogle Scholar
• Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;209(5):209ra151.
   Google Scholar
• Frias JP, Bastyr EJ, Vignati L, et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab. 2017;26(2):343–352.
   PubMed Web of Science ®Google Scholar
• Pathak NM, Pathak V, Gault VA, et al. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential. Biochem Pharmacol. 2018;155:264–274.
   PubMed Web of Science ®Google Scholar
• Irwin N, McClean PL, Cassidy RS, et al. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide. Diabetes Metab Res Rev. 2007;23(7):572–579.
   PubMedGoogle Scholar
• Gault VA, Kerr BD, Harriott P, et al. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Clin Sci. 2011;121(3):107–117.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT02205528. Available from: https://clinicaltrials.gov/ct2/show/NCT02205528?term=NNC0090-2746&draw=2&rank=1. [cited 2021 Nov 19].
   Google Scholar
• Portron A, Jadidi S, Sarkar N, et al. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects. Diabetes Obes Metab. 2017;19(10):1446–1453.
   PubMedGoogle Scholar
• Schmitt C, Portron A, Jadidi S, et al. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. Diabetes Obes Metab. 2017;19(10):1436–1445.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT05521256. Available from: https://clinicaltrials.gov/ct2/show/NCT05521256?term=Novo+Nordisk&recrs=ab&phase=04&draw=3&rank=3. [cited 2021 Nov 19].
   Google Scholar
• ClinicalTrials.gov Identifier: NCT05363774. Available from: https://clinicaltrials.gov/ct2/show/NCT05363774?term=Novo+Nordisk&recrs=ab&phase=04&draw=2&rank=5. [cited 2021 Nov 19].
   Google Scholar
• Zhang LY, Chun L, Zhang Z, et al. DA5-CH and Semaglutide protect against neurodegeneration and reduce α-Synuclein levels in the 6-OHDA Parkinson’s disease rat model. Parkinson’s Dis. 2022;2022:1428817.
   PubMedGoogle Scholar
• Li C, Liu W, Li X, et al. The novel GLP-1/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD. Brain Behav. 2020;10(3):e01505.
   PubMedGoogle Scholar
• Zhang LY, Jin QQ, Hölscher C, et al. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. Neural Regen Res. 2021;6(8):1660–1670.
   Google Scholar
• Porter DW, Irwin N, Flatt PR, et al. Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. Eur J Pharmacol. 2011;650(3):688–693.
   PubMedGoogle Scholar
• Lennox R, Porter DW, Flatt PR, et al. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice. Neuropharmacology. 2014;86:22–30.
   PubMed Web of Science ®Google Scholar
• Vyavahare SS, Mieczkowska A, Flatt PR, et al. GIP analogues augment bone strength by modulating bone composition in diet-induced obesity in mice. Peptides. 2020;125:170207.
   PubMedGoogle Scholar
• Stensen S, Gasbjerg LS, Krogh LL, et al. Effects of endogenous GIP in patients with type 2 diabetes. Eur J Endocrinol. 2021;185(1):33–45.
   PubMedGoogle Scholar
• Mansur SA, Mieczkowska A, Flatt PR, et al. The GLP-1 receptor agonist exenatide ameliorates bone composition and tissue material properties in high fat fed diabetic mice. Front Endocrinol. 2019;12(10):51.
   Google Scholar
• Mabilleau G, Perrot R, Flatt PR, et al. High fat-fed diabetic mice present with profound alterations of the osteocyte network. Bone. 2016;90:99–106.
   PubMedGoogle Scholar
• Mansur SA, Mieczkowska A, Flatt PR, et al. Sitagliptin alters bone composition in high-fat-fed mice. Calcif Tissue Int. 2019;104(4)437–448.
   PubMedGoogle Scholar
• Mabilleau G, Chappard D, Flatt PR, et al. Effects of anti-diabetic drugs on bone metabolism. Exp Rev Endocrinol Metab. 2015;10(6):663–675.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT05556512. Available from: https://clinicaltrials.gov/ct2/show/NCT05556512?term=tirzepatide&draw=2&rank=9. [cited 2021 Nov 16].
   Google Scholar
• Tchang BG, Aras M, Kumar RB, et al. Pharmacologic treatment of overweight and obesity in adults. In: Feingold KR, Anawalt B, Boyce A, et al., (editors) Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279038/.
   Google Scholar
• Usui R, Yabe D, Seino Y. Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity. J Diabetes Investig. 2019;10(4):902–905.
   PubMed Web of Science ®Google Scholar
• Lim JU, Lee JH, Kim JS, et al. Comparison of world health organization and Asia-Pacific body mass index classifications in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017;12:2465–2475
   PubMed Web of Science ®Google Scholar
• Ren Q, Chen S, Chen X, et al. An effective glucagon-like peptide-1 receptor agonists, semaglutide, improves sarcopenic obesity in obese mice by modulating skeletal muscle metabolism. Drug Des Devel Ther. 2022;16:3723–3735
   PubMed Web of Science ®Google Scholar
• Holst JJ. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr Opin Pharmacol. 2013;13:983–988.
   PubMed Web of Science ®Google Scholar
• Lafferty RA, Flatt PR, Irwin N. Is polypharmacy the future for pharmacological management of obesity? Curr. Opin Endo Metab Res. 2022;23:100322
   Google Scholar
• Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–113.
   PubMed Web of Science ®Google Scholar
• Brown JC, Pederson RA, Jorpes E, et al. Preparation of highly active enterogastrone. Can J Physiol Pharmacol. 1969;47:113–114.
   PubMed Web of Science ®Google Scholar
• Brown JC, Mutt V, Pederson RA. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol. 1970;209:57–64.
   PubMed Web of Science ®Google Scholar
• Bailey CJ. GIP analogues and the treatment of obesity-diabetes. Peptides. 2020;125:170202.
   PubMedGoogle Scholar
• Marks V. GIP: the obesity hormone. In: James WPT, Parker SW, editors. Current Approaches: obesity. Southampton (England): Duphar Medical Relations; 1988. p. 13–19.
   Google Scholar
• Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8(7):738–742.
   PubMed Web of Science ®Google Scholar
• Ayala JE, Bracy DP, James FD, et al. Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology. 2010;151(10):4678–4687.
   PubMedGoogle Scholar
• Getty-Kaushik L, Song DH, Boylan MO, et al. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity. 2006;14(7):1124–1131.
   PubMedGoogle Scholar
• Yip RG, Boylan MO, Kieffer TJ, et al. Functional GIP receptors are present on adipocytes. Endocrinology. 1998;139(9):4004–4007.
   PubMed Web of Science ®Google Scholar
• English A, Craig SL, Flatt PR, et al. Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytes. Biol Chem. 2020;401(11):1293–1303.
   PubMedGoogle Scholar
• Boylan MO, Glazebrook PA, Tatalovic M, et al. Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice. Am J Physiol Endocrinol Metab. 2015;309(12):E1008–18.
   PubMed Web of Science ®Google Scholar
• McClean PL, Gault VA, Irwin N, et al. Daily administration of the GIP-R antagonist (Pro3) GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3) GIP. Diabetes Obes Metab. 2008;10(4):336–342.
   PubMedGoogle Scholar
• Killion EA, Wang J, Yie J, et al. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med. 2018;10(472):eaat3392.
   PubMedGoogle Scholar
• Kaneko K, Fu Y, Lin HY, et al. Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition. J Clin Invest. 2019;129(9):3786–3791.
   PubMedGoogle Scholar
• Gault VA, Irwin N, Green BD, et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes. 2005;54:2436–2446.
   PubMed Web of Science ®Google Scholar
• McClean PL, Irwin N, Cassidy RS, et al. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab. 2007;293(6):1746–1755.
   PubMed Web of Science ®Google Scholar
• Chen J, Zheng S, Hu Y, et al. Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor correct obesity, dyslipidemia and nephropathy in rodent animals. Life Sci. 2021;269:119038.
   PubMedGoogle Scholar
• Killion EA, Chen M, Falsey JR, et al. Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. Nat Commun. 2020;11(1):4981.
   PubMed Web of Science ®Google Scholar
• West JA, Tsakmaki A, Ghosh SS, et al. Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism. PLoS One. 2021;16(3):e0249239.
   PubMedGoogle Scholar
• Yang B, Gelfanov VM, El K, et al. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems. Mol Metab. 2022;2022:101638.
   Google Scholar
• Pathak V, Vasu S, Gault VA, et al. Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice. Diabetologia. 2015;58:2144–2153.
   PubMedGoogle Scholar
• Lu SC, Chen M, Atangan L, et al. GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys. Cell Rep Med. 2021;2:100263
   PubMedGoogle Scholar